Pseudoprogression after Radiochemotherapy for High-grade Glioma_West China Medical Journal

Authors：

Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding?author：

Keywords：

膠質瘤; 假性進展; 替莫唑胺; 放化療

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【摘要】　目的　探討高級別膠質瘤患者放射、化學治療后假性進展的臨床特點、診斷與處理。　方法　分析2008年6月-2009年6月接受綜合治療的31例高級別膠質瘤患者臨床資料，對假性進展的患者進行回顧分析，按照實體瘤療效評判標準應用磁共振進行療效評價。　結果　 31例術后病理診斷為高級別膠質瘤的患者，替莫唑胺（TMZ）同期放射、化學治療后維持TMZ輔助化學療法，放射治療后早期發生假性進展4例（14%)。　結論　對于TMZ同期放射、化學治療后早期出現的影像學疑似進展，不要急于下結論，了解假性進展的臨床特點，結合功能影像學檢查可能會有助于臨床醫生的判斷與處理。
【Abstract】　Objective　 To discuss the clinical feature, diagnosis, and management of pseudoprogression after radiochemotherapy of high-grade glioma patients. 　Methods　 The clinical data of 31 high-grade glioma patients who underwent postoperative radiochemotherapy from June 2008 to June 2009 were reviewed. Pseudoprogression cases were analyzed. The treatment response was assessed through magnetic resonance imaging (MRI) according to the established response evaluation criteria in solid tumors.　Results　 All the 31 high grade gioma patients received postoperative fractioned radiotherapy with concomitant TMZ chemotherapy, followed by TMZ maintenance chemotherapy. Four cases of pseudoprogression occurred after radiotherapy (14%).　Conclusion　 Doctors should be careful in making early diagnosis for the suspected early progression after TMZ concomitant radiochemotherapy. It would be helpful for management to combine the clinical features of pseudoprogression with functional imaging technology.

Citation： Pseudoprogression after Radiochemotherapy for Highgrade Glioma. Pseudoprogression after Radiochemotherapy for High-grade Glioma. West China Medical Journal, 2011, 26(4): 513-516. doi: Copy

1.	Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Eng J Med, 2005, 352(10): 987-996.
2.	Clarke JL, Iwamoto FM, Sul J, et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma[J]. J Clin Oncol, 2009, 27(23): 3861-3867.
3.	Hoffman WF, Levin VA, Wilson CB. Evaluation of malignant glioma patients during the postirradiation period[J]. J Neurosurg, 1979, 50(5): 624-628.
4.	de Witt MC, de Bruin HG, Ejkenboom W, et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression[J]. Neurology, 2004, 63(3): 535-537.
5.	Chaskis C, Neyns B, Michotte A, et al. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma:clinical observation and working recommendations[J]. Surg Neurol, 2009, 72(4): 423-428.
6.	Chamberlain MC, Glantz MJ, Chalmers L, et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma[J]. J Neurooncol, 2007, 82(1): 81-83.
7.	李剛, 牟永告, 魏大年, 等. 綜合治療中腦膠質瘤的假性進展(附15例報告)[J]. 中國神經精神疾病雜志, 2009, 35(7):409-412.
8.	Rodemann HP, Blaese MA. Responses of normal cells to ionizing radiation[J]. Semin Radiat Oncol, 2007, 17(2): 81-88.
9.	Wong CS, van der Kogel AJ. Mechanisms of radiation injury to the central nervous system: implications for neuroprotection[J]. Mol Interv, 2004, 4(5): 273-284.
10.	Nordal RA, Nagy A, Pintilie M, et al. Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor[J]. Clin Cancer Res, 2004, 10(10): 3342-3353.
11.	Danson SJ, Middleton MR. Temozolomide: a novel oral alkylating agent[J]. Expert Rev Anticancer Ther, 2001, 1(1):13-19.
12.	Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients[J]. J Clin Oncol, 2008, 26 (13): 2192-2197.
13.	Weybright P, Sundgren PC, Maly P, et al. Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy[J]. AJR Am J Roentgenol, 2005, 185(6): 1471-1476.
14.	Rock JP, Scarpace L, Hearshen D, et al. Associations among magnetic resonance sperctroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis[J]. Neurosurgery, 2004, 54(5): 1111-1117.
15.	Jeon HJ, Kong DS, Park KB, et al. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience[J]. Clin Neurol Neurosurg, 2009, 111(8): 679-682.
16.	Chen W. Clinical applications of PET in brain tumors[J]. J Nucl Med, 2007, 48(9): 1468-1481.

1. 　Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Eng J Med, 2005, 352(10): 987-996.
2. 　Clarke JL, Iwamoto FM, Sul J, et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma[J]. J Clin Oncol, 2009, 27(23): 3861-3867.
3. 　Hoffman WF, Levin VA, Wilson CB. Evaluation of malignant glioma patients during the postirradiation period[J]. J Neurosurg, 1979, 50(5): 624-628.
4. 　de Witt MC, de Bruin HG, Ejkenboom W, et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression[J]. Neurology, 2004, 63(3): 535-537.
5. 　Chaskis C, Neyns B, Michotte A, et al. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma:clinical observation and working recommendations[J]. Surg Neurol, 2009, 72(4): 423-428.
6. 　Chamberlain MC, Glantz MJ, Chalmers L, et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma[J]. J Neurooncol, 2007, 82(1): 81-83.
7. 　李剛, 牟永告, 魏大年, 等. 綜合治療中腦膠質瘤的假性進展(附15例報告)[J]. 中國神經精神疾病雜志, 2009, 35(7):409-412.
8. 　Rodemann HP, Blaese MA. Responses of normal cells to ionizing radiation[J]. Semin Radiat Oncol, 2007, 17(2): 81-88.
9. 　Wong CS, van der Kogel AJ. Mechanisms of radiation injury to the central nervous system: implications for neuroprotection[J]. Mol Interv, 2004, 4(5): 273-284.
10. 　Nordal RA, Nagy A, Pintilie M, et al. Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor[J]. Clin Cancer Res, 2004, 10(10): 3342-3353.
11. 　Danson SJ, Middleton MR. Temozolomide: a novel oral alkylating agent[J]. Expert Rev Anticancer Ther, 2001, 1(1):13-19.
12. 　Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients[J]. J Clin Oncol, 2008, 26 (13): 2192-2197.
13. 　Weybright P, Sundgren PC, Maly P, et al. Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy[J]. AJR Am J Roentgenol, 2005, 185(6): 1471-1476.
14. 　Rock JP, Scarpace L, Hearshen D, et al. Associations among magnetic resonance sperctroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis[J]. Neurosurgery, 2004, 54(5): 1111-1117.
15. 　Jeon HJ, Kong DS, Park KB, et al. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience[J]. Clin Neurol Neurosurg, 2009, 111(8): 679-682.
16. 　Chen W. Clinical applications of PET in brain tumors[J]. J Nucl Med, 2007, 48(9): 1468-1481.

West China Medical Journal

Pseudoprogression after Radiochemotherapy for High-grade Glioma

Abstract Full text Figures/Tables Video References Cited by

Format

Content